Skip to content

Psilocybin: all studies

Page 116 of 440: studies 1,151 to 1,160 of 4,400, newest first. Back to the psilocybin overview

Research

Psilocybin for anorexia nervosa: If it helps, let's learn how.

Med September 8, 2023 Evelyn Attia, Joanna E Steinglass 7 citations

Existing treatments for adults with anorexia nervosa (AN) have limited effectiveness. AN is a brain-based disorder with behavioral and cognitive features leading to severe undernourishment. Peck et al. conducted a small open trial suggesting safety and tolerability of psilocybin for AN,1 opening an avenue for further investigation into the neural mechanisms involved.

DOI: 10.1016/j.medj.2023.08.003 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Eating disorders Mental health treatment Psilocybin research +1

Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study

Brain, Behavior, and Immunity September 7, 2023 Natasha L. Mason, Attila Szabo, Kim P. C. Kuypers et al. 83 citations

Patients characterized by stress-related disorders such as depression display elevated circulating concentrations of pro-inflammatory cytokines and a hyperactive HPA axis. Psychedelics are demonstrating promising results in treatment of such disorders, however the mechanisms of their therapeutic effects are still unknown. To date the evidence of acute and persisting effects of psychedelics on...

Potential Benefits of Psilocybin for Lupus Pain: A Case Report

Current Rheumatology Reviews September 6, 2023 Christine Alexopoulos, Sofia Audrey B. Gonzales, Daniel G. Arkfeld 6 citations

Introduction: Outcomes of treatment for patients with Lupus have shown overall improvement and benefit from the more aggressive use of immunosuppressants and biological agents through a treat-to-target approach. However, chronic musculoskeletal pain can be refractory to treatment despite the use of non-steroidal anti-inflammatory drugs, corticosteroids, and other analgesic agents, leading to...

DOI: 10.2174/1573397119666230904150750 (opens in new tab) Psilocybin Chronic pain Systemic lupus erythematosus Neuropathic pain +6

Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development

Psychedelic Medicine September 6, 2023 Marc J. Weintraub, Jessica K Jeffrey, Charles S. Grob et al. 4 citations

The trial will provide preliminary data on the feasibility, safety, acceptability, and psychosocial effects of PA-CBT. Results will inform randomized clinical trials to test the effects of PA-CBT for patients with depression and other mental health conditions, as well as hypotheses concerning mediating mechanisms at the cognitive and affective levels. ClinicalTrials.gov ID: NCT05227612.

Acute effects of psilocybin, LSD, mescaline found to be similar

The Brown University Psychopharmacology Update September 3, 2023

Vitamin D3, omega-3s show no protection against late-life depression Some older adults with subthreshold depression or at high risk for depression might have elevated inflammation or poor vascular and metabolic health, suggesting that supplementation could improve mood in these individuals. An ancillary study to a trial of vitamin D3 and omega-3 fatty acids examined the effects of these...

Comparison of fragrance and flavor components in non-psilocybin and psilocybin mushrooms using vacuum-assisted headspace high-capacity solid-phase microextraction and gas chromatography–mass spectrometry

Advances in Sample Preparation September 2, 2023 Shannon L. Thomas, Colton Myers, Kevin A Schug 13 citations

Vacuum-assisted headspace high capacity solid-phase microextraction (Vac-HS-HC-SPME) coupled with gas chromatography–mass spectrometry (GC–MS) was used to compare the volatile compounds that make up the volatile and semi-volatile components of five psilocybin mushrooms (Psilocybe cubensis), as well as three non-psilocybin mushroom species. Using an untargeted analysis, common volatiles detected...

DOI: 10.1016/j.sampre.2023.100090 (opens in new tab) Psilocybin Solid-phase microextraction Gas chromatography–mass spectrometry Mushroom

HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer.

Journal of Pain and Symptom Management September 1, 2023 Benjamin R. Lewis, Eric L Garland, Kevin Byrne et al. 60 citations

Psilocybin-assisted psychotherapy shows promise in treating depression and existential distress in people with serious medical illness. However, its individual-based methodology poses challenges for scaling and resource availability. The HOPE trial (A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients with Cancer) is an Institutional Review Boards-approved open-label feasibility...

Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.

Neuropsychopharmacology September 1, 2023 Guy M. Goodwin, Megan Croal, David Feifel et al. 166 citations

Psilocybin is being investigated as a treatment in adults with treatment-resistant depression (TRD). Withdrawal from serotonergic antidepressant drugs is a common prerequisite for taking part in trials of psilocybin due to the possibility of ongoing antidepressant drugs altering the psychedelic effect. This phase II, exploratory, international, fixed-dose, open-label study explored the safety,...

Psychedelics, With a Focus on Psilocybin: Issues for the Clinician.

Journal of Psychiatric Practice September 1, 2023 Amir Garakani, Jeanne L Alexander, Calvin R Sumner et al. 6 citations

There has been a burgeoning interest in psychedelics among the public, state legislatures, psychiatrists and other clinical providers, and within the research community. Increasing numbers of studies evaluating psychedelics for depression, anxiety, posttraumatic stress disorder, and substance use disorders have been conducted or are underway. While discussing psychedelics in general, the focus...

DOI: 10.1097/pra.0000000000000729 (opens in new tab) Full text (opens in new tab) Psychedelics Psilocybin therapy Mental health Clinical research

Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats.

Molecular Psychiatry September 1, 2023 Kat F. Kiilerich, Joe Lorenz, Malthe B. Scharff et al. 48 citations

Psilocybin (a classic serotonergic psychedelic drug) has received appraisal for use in psychedelic-assisted therapy of several psychiatric disorders. A less explored topic concerns the use of repeated low doses of psychedelics, at a dose that is well below the psychedelic dose used in psychedelic-assisted therapy and often referred to as microdosing. Psilocybin microdose users frequently report...